#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Myelodysplastic syndrome Neuromyelitis optica spectrum disorder Neutropenia Becker's muscular dystrophy Malignant fibrous histiocytoma Amyloidosis Cutaneous T-cell lymphoma Blastic plasmacytoid dendritic cell neoplasia Round cell liposarcoma Sjogren's syndrome Pelizaeus-Merzbacher disease Paget's disease of the vulva Non-Hodgkin's lymphoma unspecified histology aggressive recurrent Autoimmune myositis Liposarcoma More trials…

    Learn about Rare Diseases

    Atypical teratoid/rhabdoid tumour of CNS – Trials in Disease Myelodysplastic syndrome – Treatment Waldenstrom’s macroglobulinaemia – Trials in Disease Osteosarcoma metastatic – Life with Disease Ewing’s sarcoma metastatic – Basic Information Biotinidase deficiency – Diagnostics Ornithine transcarbamoylase deficiency – Trials in Disease Short-bowel syndrome – Trials in Disease Ocular melanoma – Treatment Hyperoxaluria More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ilofotase Alfa Gsk3915393 Mycophenolate Mofetil Alclometasone Dipropionate Albiglutide Hydroxychloroquine Sulfate Inupadenant Alanyl Glutamine Emtricitabine Human Plasma Protein Atomoxetine Hydrochloride Axicabtagene Ciloleucel GSK3862995B Methylone Fludrocortisone Intestifix Acoramidis Hydrochloride Dexrazoxane Setanaxib Volrustomig More therapies…

    Learn about Your Condition

    Pseudomonas infection Squamous cell carcinoma Oesophagectomy Malignant mast cell neoplasm Lip and/or oral cavity cancer Myocardial ischaemia Arteriovenous graft thrombosis Renal cell carcinoma Poor quality sleep Burkitt's lymphoma Myocarditis Procedural anxiety Ulcerative keratitis Lung cancer metastatic Acute kidney injury More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Fakultni Nemocnice Plzen

Fakultni Nemocnice Plzen

Edvarda Benese 1128/13, Jizni Predmesti, Plzen, 301 00, Czechia

Want to learn more about this study or check if you can participate? Contact us.

  • Study on How Gadoquatrane Works and Its Safety in Children Undergoing MRI Scans

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Magnetic resonance imaging
    Investigated Drugs:
    • Gadoquatrane
    Bulgaria Czechia Germany Hungary Italy Poland +1

  • A study of ziltivekimab compared to placebo for reducing heart problems in patients who have had a heart attack

    Not recruiting

    3 1
    Investigated Diseases:
    • Acute myocardial infarction
    Investigated Drugs:
    • Ziltivekimab
    Bulgaria Czechia Denmark France Germany Greece +4

  • A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

    Not recruiting

    3 1
    Investigated Diseases:
    • Cardiac failure
    Investigated Drugs:
    • Ziltivekimab
    Austria Belgium Bulgaria Croatia Czechia Denmark +18

  • Study of ritlecitinib for treating severe alopecia areata in children aged 6 to under 12 years

    Not recruiting

    3 1
    Czechia France Italy Poland Spain

  • Study of Orticumab in Adults with Previous Heart Attack and High Coronary Inflammation Measured by CT Scan

    Not recruiting

    2 1
    Czechia Hungary Italy Poland Romania Spain +1

  • Study on the Effects of Ritlecitinib in Patients Aged 12 and Older with Alopecia Areata

    Not recruiting

    3 1 1
    Czechia Poland Spain

  • Study on Long-term Safety and Effectiveness of ESK-001 for Patients with Moderate to Severe Plaque Psoriasis

    Not recruiting

    3 1
    Investigated Drugs:
    • Envudeucitinib
    Austria Belgium Bulgaria Czechia Estonia France +7

  • Study on Itepekimab for Adults with Chronic Rhinosinusitis and Nasal Polyps

    Not recruiting

    3 1
    Investigated Diseases:
    • Chronic rhinosinusitis with nasal polyps
    Investigated Drugs:
    • Itepekimab
    Belgium Czechia Denmark France Germany Hungary +5

  • Study of Quizartinib with Chemotherapy for Adults with Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Quizartinib Dihydrochloride
    • Idarubicin Hydrochloride
    • Daunorubicin Hydrochloride
    Austria Belgium Bulgaria Croatia Czechia France +9

  • Study on the Safety and Effectiveness of AZD8630 for Adults with Uncontrolled Asthma at Risk of Exacerbations

    Not recruiting

    2 1
    Investigated Diseases:
    • Asthma
    Investigated Drugs:
    • Azd8630
    • Human Igg1 Lambda Fab Fragment Against Thymic Stromal Lymphopoietin
    Belgium Czechia Denmark France Germany Italy +3
Previous Page
1 … 3 4 5 6 7 … 10
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!